|         |                                                                                                                                                                                                                                                                                                                                                |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Net loss attributable to DaVita Inc. for the quarter ended September 30, 2017 was $(214) million, or $(1.14) per share, which included non-cash goodwill impairment charges related to our DMG reportable segment, and net income for the nine months ended September 30, 2017 was $360 million, or $1.86 per share. |

|         |                                                                                                                                                                                                                                                 |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Adjusted net income attributable to DaVita Inc. for the quarter ended September 30, 2017 was $155 million, or $0.81 per share, and for the nine months ended September 30, 2017 was $487 million, or $2.52 per share. |

|         |                                                                                                                                                                                                                                                                                     |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Adjusted net income attributable to DaVita Inc., further adjusted to exclude amortization for the quarter ended September 30, 2017, was $185 million, or $0.97 per share, and for the nine months ended September 30, 2017, was $575 million, or $2.97 per share. |

|         |                                                                                                                                                                                                                      |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Net income attributable to DaVita Inc. for the quarter ended September 30, 2016 was $571 million, or $2.76 per share, and for the nine months ended September 30, 2016 was $722 million, or $3.48 per share. |

|         |                                                                                                                                                                                                                               |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Adjusted net income attributable to DaVita Inc. for the quarter ended September 30, 2016 was $197 million, or $0.95 per share, and for the nine months ended September 30, 2016 was $597 million, or $2.88 per share. |

|         |                                                                                                                                                                                                                                                                         |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Adjusted net income attributable to DaVita Inc., further adjusted to exclude amortization for the quarter ended September 30, 2016 was $223 million, or $1.08 per share, and for the nine months ended September 30, 2016 was $675 million, or $3.25 per share. |

----

----

----

|         |                                                                                                                                          |
|---------|------------------------------------------------------------------------------------------------------------------------------------------|
| • | We are updating our adjusted consolidated operating income guidance for 2017 to be in the range of $1.620 billion to $1.685 billion. |

|         |                                                                                                                                             |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------|
| • | We are updating our adjusted operating income guidance for Kidney Care for 2017 to be in the range of $1.570 billion to $1.600 billion. |

|         |                                                                                                                              |
|---------|------------------------------------------------------------------------------------------------------------------------------|
| • | We expect our operating income guidance for Kidney Care for 2018 to be in the range of $1.500 billion to $1.600 billion. |

|         |                                                                                                                                            |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------|
| • | We are updating our adjusted consolidated operating income guidance for DMG for 2017 to be in the range of $50 million to $85 million. |

|         |                                                                                                                                                                                         |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | We still expect our consolidated operating cash flow guidance for 2017 to be in the range of $1.750 billion to $1.950 billion, which includes the net benefit of the VA settlement. |

|         |                                                                                                                                   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------|
| • | We still expect our 2017 guidance for adjusted effective tax rate attributable to DaVita Inc. to be approximately 39.0% to 40.0%. |

----

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates, and a reduction in the number of patients under such plans, including as a result of restrictions or prohibitions on the use and/or availability of charitable premium assistance, which may result in the loss of revenues or patients, or our making incorrect assumptions about how our patients will respond to any change in financial assistance from charitable organizations; |

|         |                                                                                                                                                                                                                                                                                                                                                                     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the extent to which the ongoing implementation of healthcare exchanges or changes in or new legislation, regulations or guidance, or enforcement thereof, including among other things those regarding the exchanges, results in a reduction in reimbursement rates for our services from and/or the number of patients enrolled in higher-paying commercial plans; |

|         |                                                                                                                                |
|---------|--------------------------------------------------------------------------------------------------------------------------------|
| • | a reduction in government payment rates under the Medicare End Stage Renal Disease program or other government-based programs; |

|         |                                                           |
|---------|-----------------------------------------------------------|
| • | the impact of the Medicare Advantage benchmark structure; |

|         |                                                                                                                                                                                                                                                    |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | risks arising from potential and proposed federal and/or state legislation or regulation, including healthcare-related and labor-related legislation or regulation, that could have a material adverse effect on our operations and profitability; |

|         |                                                                                                                                                                                                                                                                                          |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the impact of the changing political environment and related developments on the current health care marketplace and on our business, including with respect to the future of the Affordable Care Act, the exchanges and many other core aspects of the current health care marketplace; |

|         |                                                                                                                |
|---------|----------------------------------------------------------------------------------------------------------------|
| • | changes in pharmaceutical or anemia management practice patterns, payment policies, or pharmaceutical pricing; |

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | legal compliance risks, including our continued compliance with complex government regulations and the provisions of our current corporate integrity agreement and current or potential investigations by various government entities and related government or private-party proceedings, and restrictions on our business and operations required by our corporate integrity agreement and other current or potential settlement terms, and the financial impact thereof and our ability to recover any losses related to such legal matters from third parties; |

|         |                                                                                                                |
|---------|----------------------------------------------------------------------------------------------------------------|
| • | continued increased competition from large- and medium-sized dialysis providers that compete directly with us; |

|         |                                                                                                                                                                                                               |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | our ability to reduce administrative expenses while maintaining targeted levels of service and operating performance, including our ability to achieve anticipated savings from our recent DMG restructuring; |

|         |                                                                                                                                                                                                                                                                                                                                                                            |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | our ability to maintain contracts with physician medical directors, changing affiliation models for physicians, and the emergence of new models of care introduced by the government or private sector that may erode our patient base and reimbursement rates, such as accountable care organizations, independent practice associations and integrated delivery systems; |

----

|         |                                                                                                                                                                                                                                                                                                                                                                          |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | our ability to complete acquisitions, mergers or dispositions that we might be considering or announce, or to integrate and successfully operate any business we may acquire or have acquired, including DMG, or to successfully expand our operations and services to markets outside the United States, or to businesses outside of dialysis and DMG’s business; |

|         |                                                                                                                                                                                                       |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | noncompliance by us or our business associates with any privacy laws or any security breach involving the misappropriation, loss or other unauthorized use or disclosure of confidential information; |

|         |                                    |
|---------|------------------------------------|
| • | the variability of our cash flows; |

|         |                                                                                                                                                                                                                                                   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the risk that we might invest material amounts of capital and incur significant costs in connection with the growth and development of our international operations, yet we might not be able to operate them profitably anytime soon, if at all; |

|         |                                                                                                                |
|---------|----------------------------------------------------------------------------------------------------------------|
| • | risks arising from the use of accounting estimates, judgments and interpretations in our financial statements; |

|         |                                                        |
|---------|--------------------------------------------------------|
| • | impairment of our goodwill or other intangible assets; |

|         |                                                                                                                                |
|---------|--------------------------------------------------------------------------------------------------------------------------------|
| • | the risk that laws regulating the corporate practice of medicine could restrict the manner in which DMG conducts its business; |

|         |                                                                                                        |
|---------|--------------------------------------------------------------------------------------------------------|
| • | the risk that the cost of providing services under DMG’s agreements may exceed our compensation; |

|         |                                                                                                                                                                                    |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the risk that reductions in reimbursement rates, including Medicare Advantage rates, and future regulations may negatively impact DMG’s business, revenue and profitability; |

|         |                                                                                                                                                                                   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the risk that DMG may not be able to successfully establish a presence in new geographic regions or successfully address competitive threats that could reduce its profitability; |

|         |                                                                                                                                                           |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the risk that a disruption in DMG’s healthcare provider networks could have an adverse effect on DMG’s business operations and profitability; |

|         |                                                                                                                                                                    |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the risk that reductions in the quality ratings of health maintenance organization plan customers of DMG could have an adverse effect on DMG’s business; and |

|         |                                                                                                                                                                              |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | the risk that health plans that acquire health maintenance organizations may not be willing to contract with DMG or may be willing to contract only on less favorable terms. |

----

|                                                                                                  |
|--------------------------------------------------------------------------------------------------|
|                                                                                                  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                                                                             | Three months endedSeptember 30, |   | Nine months ended September 30, |
|                                                                                             | 2017 |   | 2016 |   | 2017 |   | 2016 |
| Patient service revenues                                                                         | $ | 2,746,257 |  |   | $ | 2,643,194 |  |   | $ | 8,030,102 |  |   | $ | 7,708,641 |  |
| Less: Provision for uncollectible accounts                                                       | (123,760 | ) |   | (115,555 | ) |   | (352,228 | ) |   | (336,188 | ) |
|      Net patient service revenues                                       | 2,622,497 |  |   | 2,527,639 |  |   | 7,677,874 |  |   | 7,372,453 |  |
| Capitated revenues                                                                               | 1,016,365 |  |   | 872,538 |  |   | 2,956,479 |  |   | 2,660,532 |  |
| Other revenues                                                                                   | 283,969 |  |   | 330,399 |  |   | 863,238 |  |   | 996,378 |  |
| Total net revenues                                                                               | 3,922,831 |  |   | 3,730,576 |  |   | 11,497,591 |  |   | 11,029,363 |  |
| Operating expenses and charges:                                                                  |   |  |   |   |  |   |   |  |   |   |  |
|      Patient care costs and other costs                                 | 2,925,975 |  |   | 2,697,629 |  |   | 8,508,706 |  |   | 7,950,987 |  |
|      General and administrative                                         | 400,018 |  |   | 406,890 |  |   | 1,174,113 |  |   | 1,180,214 |  |
|      Depreciation and amortization                                      | 203,283 |  |   | 181,739 |  |   | 593,527 |  |   | 531,475 |  |
|      Provision for uncollectible accounts                               | (2,685 | ) |   | 3,773 |  |   | (1,381 | ) |   | 9,856 |  |
|      Equity investment loss (income)                                    | 4,852 |  |   | (4,237 | ) |   | (2,697 | ) |   | (5,119 | ) |
|      Goodwill and asset impairment charges                              | 601,040 |  |   | — |  |   | 701,523 |  |   | 253,000 |  |
|      Gain on changes in ownership interests, net                        | (17,129 | ) |   | (374,374 | ) |   | (23,402 | ) |   | (404,165 | ) |
|      Gain on settlement, net                                            | — |  |   | — |  |   | (526,827 | ) |   | — |  |
|           Total operating expenses and charges | 4,115,354 |  |   | 2,911,420 |  |   | 10,423,562 |  |   | 9,516,248 |  |
| Operating (loss) income                                                                          | (192,523 | ) |   | 819,156 |  |   | 1,074,029 |  |   | 1,513,115 |  |
| Debt expense                                                                                     | (109,623 | ) |   | (104,581 | ) |   | (322,014 | ) |   | (310,359 | ) |
| Other income, net                                                                                | 4,370 |  |   | 1,876 |  |   | 13,866 |  |   | 8,067 |  |
| (Loss) income before income taxes                                                                | (297,776 | ) |   | 716,451 |  |   | 765,881 |  |   | 1,210,823 |  |
| Income tax (benefit) expense                                                                     | (125,742 | ) |   | 104,301 |  |   | 276,005 |  |   | 366,011 |  |
| Net (loss) income                                                                                | (172,034 | ) |   | 612,150 |  |   | 489,876 |  |   | 844,812 |  |
|      Less: Net income attributable to noncontrolling interests          | (42,442 | ) |   | (40,818 | ) |   | (129,654 | ) |   | (122,664 | ) |
| Net (loss) income attributable to DaVita Inc.                                                    | $ | (214,476 | ) |   | $ | 571,332 |  |   | $ | 360,222 |  |   | $ | 722,148 |  |
| Earnings per share:                                                                              |   |  |   |   |  |   |   |  |   |   |  |
| Basic net (loss) income per share attributable to DaVita Inc.                                    | $ | (1.14 | ) |   | $ | 2.80 |  |   | $ | 1.89 |  |   | $ | 3.54 |  |
| Diluted net (loss) income per share attributable to DaVita Inc.                                  | $ | (1.14 | ) |   | $ | 2.76 |  |   | $ | 1.86 |  |   | $ | 3.48 |  |
| Weighted average shares for earnings per share:                                                  |   |   |   |   |   |   |   |
|      Basic                                                              | 188,883,922 |  |   | 203,761,433 |  |   | 190,770,165 |  |   | 204,206,979 |  |
|      Diluted                                                            | 188,883,922 |  |   | 206,961,450 |  |   | 193,546,245 |  |   | 207,643,794 |  |

----

|                                                                                                  |
|--------------------------------------------------------------------------------------------------|
|                                                                                                  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                                                                             | Three months endedSeptember 30, |   | Nine months endedSeptember 30, |
|                                                                                             | 2017 |   | 2016 |   | 2017 |   | 2016 |
| Net (loss) income                                                                                | $ | (172,034 | ) |   | $ | 612,150 |  |   | $ | 489,876 |  |   | $ | 844,812 |  |
| Other comprehensive (loss) income, net of tax:                                                   |   |  |   |   |  |   |   |  |   |   |  |
| Unrealized losses on interest rate cap and swap agreements:                                      |   |  |   |   |  |   |   |  |   |   |  |
| Unrealized losses on interest rate cap and swap agreements                                       | (478 | ) |   | (153 | ) |   | (5,479 | ) |   | (8,238 | ) |
| Reclassifications of net rate cap and swap agreements realized losses into net (loss) income     | 1,265 |  |   | 388 |  |   | 3,793 |  |   | 1,301 |  |
| Unrealized gains on investments:                                                                 |   |  |   |   |   |   |  |   |   |  |
| Unrealized gains on investments                                                                  | 863 |  |   | 1,121 |  |   | 3,478 |  |   | 1,988 |  |
| Reclassification of net investment realized gains into net (loss) income                    | (9 | ) |   | (50 | ) |   | (221 | ) |   | (143 | ) |
| Unrealized gains on foreign currency translation:                                                |   |  |   |   |  |   |   |  |   |   |  |
| Foreign currency translation adjustments                                                         | 29,143 |  |   | (951 | ) |   | 91,546 |  |   | 5,386 |  |
| Reclassification of foreign currency translation adjustment realized loss into net (loss) income | — |  |   | 7,513 |  |   | — |  |   | 7,513 |  |
| Other comprehensive income                                                                       | 30,784 |  |   | 7,868 |  |   | 93,117 |  |   | 7,807 |  |
| Total comprehensive (loss) income                                                                | (141,250 | ) |   | 620,018 |  |   | 582,993 |  |   | 852,619 |  |
| Less: Comprehensive income attributable to noncontrolling interests                              | (42,442 | ) |   | (40,876 | ) |   | (129,652 | ) |   | (122,871 | ) |
| Comprehensive (loss) income attributable to DaVita Inc.                                          | $ | (183,692 | ) |   | $ | 579,142 |  |   | $ | 453,341 |  |   | $ | 729,748 |  |

----

|                                                                                             |
|---------------------------------------------------------------------------------------------|
|                                                                                             |  |  |  |  |  |  |  |
|                                                                                        | Nine months endedSeptember 30, |
|                                                                                        | 2017 |   | 2016 |
| Cash flows from operating activities:                                                       |   |  |   |   |  |
| Net income                                                                                  | $ | 489,876 |  |   | $ | 844,812 |  |
| Adjustments to reconcile net income to net cash provided by operating activities:           |   |  |   |   |  |
| Depreciation and amortization                                                               | 593,527 |  |   | 531,475 |  |
| Goodwill and asset impairment charges                                                       | 701,523 |  |   | 253,000 |  |
| Stock-based compensation expense                                                            | 28,478 |  |   | 29,817 |  |
| Deferred income taxes                                                                       | (132,781 | ) |   | 48,778 |  |
| Equity investment income, net                                                               | 19,071 |  |   | 16,825 |  |
| Gain on changes in ownership interests, net                                                 | (23,402 | ) |   | (404,165 | ) |
| Other non-cash charges                                                                      | 41,709 |  |   | 9,163 |  |
| Changes in operating assets and liabilities, other than from acquisitions and divestitures: |   |   |   |  |
| Accounts receivable                                                                         | (146,024 | ) |   | (85,660 | ) |
| Inventories                                                                                 | 14,272 |  |   | (13,045 | ) |
| Other receivables and other current assets                                                  | (47,173 | ) |   | (1,616 | ) |
| Other long-term assets                                                                      | (13,831 | ) |   | 31,081 |  |
| Accounts payable                                                                            | 18,595 |  |   | (45,507 | ) |
| Accrued compensation and benefits                                                           | (60,063 | ) |   | 79,289 |  |
| Other current liabilities                                                                   | 39,445 |  |   | 119,549 |  |
| Income taxes                                                                                | 22,669 |  |   | 79,592 |  |
| Other long-term liabilities                                                                 | 18,648 |  |   | (12,126 | ) |
| Net cash provided by operating activities                                                   | 1,564,539 |  |   | 1,481,262 |  |
| Cash flows from investing activities:                                                       |   |  |   |   |  |
|      Additions of property and equipment                           | (639,829 | ) |   | (575,243 | ) |
|      Acquisitions                                                  | (726,538 | ) |   | (497,331 | ) |
|      Proceeds from asset and business sales                        | 92,529 |  |   | 18,991 |  |
|      Purchase of investments available for sale                    | (9,882 | ) |   | (9,041 | ) |
|      Purchase of investments held-to-maturity                      | (225,166 | ) |   | (976,411 | ) |
|      Proceeds from sale of investments available for sale          | 5,822 |  |   | 8,636 |  |
|      Proceeds from investments held-to-maturity                    | 398,765 |  |   | 743,941 |  |
|      Purchase of intangible assets                                 | — |  |   | (75 | ) |
|      Purchase of equity investments                                | (3,014 | ) |   | (11,629 | ) |
|      Proceeds from sale of equity investments                      | — |  |   | 40,920 |  |
|      Distributions received on equity investments                  | 80 |  |   | — |  |
| Net cash used in investing activities                                                       | (1,107,233 | ) |   | (1,257,242 | ) |
| Cash flows from financing activities:                                                       |   |  |   |   |  |
|      Borrowings                                                    | 38,160,821 |  |   | 39,102,302 |  |
|      Payments on long-term debt and other financing costs          | (38,269,284 | ) |   | (39,201,204 | ) |
|      Purchase of treasury stock                                    | (321,411 | ) |   | (620,898 | ) |
|      Distributions to noncontrolling interests                     | (165,463 | ) |   | (145,072 | ) |
|      Stock award exercises and other share issuances, net          | 15,781 |  |   | 18,515 |  |
|      Contributions from noncontrolling interests                   | 51,156 |  |   | 35,524 |  |
|      Purchase of noncontrolling interests                          | (1,432 | ) |   | (9,727 | ) |
|      Other                                                         | — |  |   | 12,584 |  |
| Net cash used in financing activities                                                       | (529,832 | ) |   | (807,976 | ) |
| Effect of exchange rate changes on cash and cash equivalents                                | 5,449 |  |   | (1,664 | ) |
| Net decrease in cash and cash equivalents                                                   | (67,077 | ) |   | (585,620 | ) |
| Cash and cash equivalents at beginning of the year                                          | 913,187 |  |   | 1,499,116 |  |
| Cash and cash equivalents at end of the period                                              | $ | 846,110 |  |   | $ | 913,496 |  |

----

|                                                                                                                                                                                                                                             |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                             |  |  |  |  |  |  |  |
|                                                                                                                                                                                                                                        | September 30,2017 |   | December 31,2016 |
| ASSETS                                                                                                                                                                                                                                      |   |  |   |   |  |
| Cash and cash equivalents                                                                                                                                                                                                                   | $ | 846,110 |  |   | $ | 913,187 |  |
| Short-term investments                                                                                                                                                                                                                      | 137,358 |  |   | 310,198 |  |
| Accounts receivable, less allowance of $221,329 and $252,056                                                                                                                                                                           | 2,091,074 |  |   | 1,917,302 |  |
| Inventories                                                                                                                                                                                                                                 | 154,422 |  |   | 164,858 |  |
| Other receivables                                                                                                                                                                                                                           | 599,374 |  |   | 453,483 |  |
| Prepaid and other current assets                                                                                                                                                                                                            | 205,211 |  |   | 210,604 |  |
| Income taxes receivable                                                                                                                                                                                                                     | — |  |   | 10,596 |  |
| Total current assets                                                                                                                                                                                                                        | 4,033,549 |  |   | 3,980,228 |  |
| Property and equipment, net of accumulated depreciation of $3,151,402 and $2,832,160                                                                                                                                                        | 3,386,056 |  |   | 3,175,367 |  |
| Intangible assets, net of accumulated amortization of $1,084,682 and $940,731                                                                                                                                                               | 1,451,033 |  |   | 1,527,767 |  |
| Equity method and other investments                                                                                                                                                                                                         | 545,053 |  |   | 502,389 |  |
| Long-term investments                                                                                                                                                                                                                       | 120,129 |  |   | 103,679 |  |
| Other long-term assets                                                                                                                                                                                                                      | 61,642 |  |   | 44,510 |  |
| Goodwill                                                                                                                                                                                                                                    | 9,415,877 |  |   | 9,407,317 |  |
|                                                                                                                                                                                                                                        | $ | 19,013,339 |  |   | $ | 18,741,257 |  |
| LIABILITIES AND EQUITY                                                                                                                                                                                                                      |   |  |   |   |  |
| Accounts payable                                                                                                                                                                                                                            | $ | 566,918 |  |   | $ | 522,415 |  |
| Other liabilities                                                                                                                                                                                                                           | 928,123 |  |   | 856,847 |  |
| Accrued compensation and benefits                                                                                                                                                                                                           | 775,280 |  |   | 815,761 |  |
| Medical payables                                                                                                                                                                                                                            | 400,259 |  |   | 336,381 |  |
| Current portion of long-term debt                                                                                                                                                                                                           | 189,822 |  |   | 165,041 |  |
| Income tax payable                                                                                                                                                                                                                          | 14,391 |  |   | — |  |
| Total current liabilities                                                                                                                                                                                                                   | 2,874,793 |  |   | 2,696,445 |  |
| Long-term debt                                                                                                                                                                                                                              | 8,908,703 |  |   | 8,947,327 |  |
| Other long-term liabilities                                                                                                                                                                                                                 | 548,226 |  |   | 465,358 |  |
| Deferred income taxes                                                                                                                                                                                                                       | 685,598 |  |   | 809,128 |  |
| Total liabilities                                                                                                                                                                                                                           | 13,017,320 |  |   | 12,918,258 |  |
| Commitments and contingencies                                                                                                                                                                                                               |   |  |   |   |  |
| Noncontrolling interests subject to put provisions                                                                                                                                                                                          | 1,026,890 |  |   | 973,258 |  |
| Equity:                                                                                                                                                                                                                                     |   |  |   |   |  |
| Preferred stock ($0.001 par value, 5,000,000 shares authorized; none issued)                                                                                                                                                                |   |  |   |   |  |
|      Common stock ($0.001 par value, 450,000,000 shares authorized; 194,788,516 and      194,554,491 shares issued and 189,231,693 and 194,554,491 shares outstanding, respectively) | 195 |  |   | 195 |  |
| Additional paid-in capital                                                                                                                                                                                                                  | 1,059,176 |  |   | 1,027,182 |  |
| Retained earnings                                                                                                                                                                                                                           | 4,070,535 |  |   | 3,710,313 |  |
| Treasury stock (5,556,823 shares at September 30, 2017)                                                                                                                                                                                     | (348,801 | ) |   | — |  |
| Accumulated other comprehensive income (loss)                                                                                                                                                                                               | 3,476 |  |   | (89,643 | ) |
| Total DaVita Inc. shareholders’ equity                                                                                                                                                                                                | 4,784,581 |  |   | 4,648,047 |  |
| Noncontrolling interests not subject to put provisions                                                                                                                                                                                      | 184,548 |  |   | 201,694 |  |
| Total equity                                                                                                                                                                                                                                | 4,969,129 |  |   | 4,849,741 |  |
|                                                                                                                                                                                                                                        | $ | 19,013,339 |  |   | $ | 18,741,257 |  |

----

|                                                                                                                                |
|--------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                                                                                                           | Three months ended |   | Nine months ended September 30, 2017 |
|                                                                                                                           | September 30,2017 |   | June 30,2017 |   | September 30,2016 |   |
| 1. Consolidated Financial Results:                                                                                             |   |   |   |   |   |   |   |
| Consolidated net revenues                                                                                                      | $ | 3,923 |  |   | $ | 3,877 |  |   | $ | 3,731 |  |   | $ | 11,498 |  |
| Operating (loss) income                                                                                                        | $ | (193 | ) |   | $ | 378 |  |   | $ | 819 |  |   | $ | 1,074 |  |
| Adjusted operating income excluding certain items(1)                                                                           | $ | 399 |  |   | $ | 436 |  |   | $ | 472 |  |   | $ | 1,227 |  |
| Operating (loss) income margin                                                                                                 | (4.9 | )% |   | 9.7 | % |   | 22.0 | % |   | 9.3 | % |
| Adjusted operating income margin excluding certain items(1) (5)                                                                | 10.2 |  % |   | 11.2 | % |   | 12.6 | % |   | 10.7 | % |
| Net (loss) income attributable to DaVita Inc.                                                                                  | $ | (214 | ) |   | $ | 127 |  |   | $ | 571 |  |   | $ | 360 |  |
| Adjusted net income attributable to DaVita Inc. excluding certain items(1)                                                     | $ | 155 |  |   | $ | 179 |  |   | $ | 197 |  |   | $ | 487 |  |
| Diluted net (loss) income per share attributable to DaVita Inc.                                                                | $ | (1.14 | ) |   | $ | 0.65 |  |   | $ | 2.76 |  |   | $ | 1.86 |  |
| Adjusted diluted net income per share attributable to DaVita Inc.  excluding certain items (1)                                 | $ | 0.81 |  |   | $ | 0.92 |  |   | $ | 0.95 |  |   | $ | 2.52 |  |
|                                                                                                                           |   |   |   |   |   |   |   |
| 2. Consolidated Business Metrics:                                                                                              |   |   |   |   |   |   |   |
| Expenses                                                                                                                       |   |   |   |   |   |   |   |
| General and administrative expenses as a percent of consolidated net revenues(2)                                          | 10.2 |  % |   | 9.9 | % |   | 10.9 | % |   | 10.2 | % |
| Consolidated effective tax rate                                                                                                | 42.2 |  % |   | 41.4 | % |   | 14.6 | % |   | 36.0 | % |
| Consolidated effective tax rate attributable to DaVita Inc.(1)                                                            | 37.0 |  % |   | 47.2 | % |   | 15.4 | % |   | 43.3 | % |
| Adjusted consolidated effective tax rate attributable to DaVita Inc.(1)                                                        | 38.3 |  % |   | 39.5 | % |   | 40.0 | % |   | 39.3 | % |
|                                                                                                                           |   |   |   |   |   |   |   |
| 3. Summary of Division Financial Results:                                                                                      |   |   |   |   |   |   |   |
|     Net revenues                                                                                           |   |   |   |   |   |   |   |
| Kidney Care:                                                                                                                   |   |   |   |   |   |   |   |
| U.S. dialysis and related lab services                                                                                         | $ | 2,370 |  |   | $ | 2,325 |  |   | $ | 2,324 |  |   | $ | 6,967 |  |
| Other—Ancillary services and strategic initiatives                                                                       |   |   |   |   |   |   |   |
| U.S. ancillary services and strategic initiatives                                                                              | 323 |  |   | 314 |  |   | 359 |  |   | 952 |  |
| International                                                                                                                  | 91 |  |   | 79 |  |   | 53 |  |   | 233 |  |
|                                                                                                                           | 414 |  |   | 394 |  |   | 412 |  |   | 1,186 |  |
| Eliminations within Kidney Care                                                                                                | (19 | ) |   | (19 | ) |   | (10 | ) |   | (57 | ) |
| Total Kidney Care                                                                                                              | 2,765 |  |   | 2,699 |  |   | 2,725 |  |   | 8,096 |  |
| DMG                                                                                                                            | 1,178 |  |   | 1,196 |  |   | 1,028 |  |   | 3,461 |  |
| Eliminations between Kidney Care and DMG                                                                                       | (21 | ) |   | (18 | ) |   | (23 | ) |   | (60 | ) |
| Total net consolidated revenues                                                                                                | $ | 3,923 |  |   | $ | 3,877 |  |   | $ | 3,731 |  |   | $ | 11,498 |  |
| Operating (loss) income                                                                                                        |   |   |   |   |   |   |   |
| Kidney Care:                                                                                                                   |   |   |   |   |   |   |   |
| U.S. dialysis and related lab services                                                                                         | $ | 443 |  |   | $ | 450 |  |   | $ | 452 |  |   | $ | 1,838 |  |
| Other—Ancillary services and strategic initiatives                                                                       |   |   |   |   |   |   |   |
| U.S. ancillary services and strategic initiatives                                                                              | (19 | ) |   | (36 | ) |   | (6 | ) |   | (108 | ) |
| International                                                                                                                  | (17 | ) |   | (13 | ) |   | 368 |  |   | (35 | ) |
|                                                                                                                           | (37 | ) |   | (48 | ) |   | 362 |  |   | (143 | ) |
| Corporate administrative support                                                                                               | (11 | ) |   | (11 | ) |   | (28 | ) |   | (33 | ) |
| Total Kidney Care                                                                                                              | 395 |  |   | 391 |  |   | 786 |  |   | 1,662 |  |
| DMG                                                                                                                            | (588 | ) |   | (13 | ) |   | 33 |  |   | (588 | ) |
|               Total consolidated operating (loss) income | $ | (193 | ) |   | $ | 378 |  |   | $ | 819 |  |   | $ | 1,074 |  |

----

|                                                        |
|--------------------------------------------------------|
|                                                        |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                                   | Three months ended |   | Nine months ended September 30, 2017 |
|                                                   | September 30,2017 |   | June 30,2017 |   | September 30,2016 |   |
| 4. Summary of Reportable Segment Financial Results:    |   |   |   |   |   |   |   |
| U.S. Dialysis and Related Lab Services                 |   |   |   |   |   |   |   |
| Revenue:                                               |   |   |   |   |   |   |   |
| Patient services revenues                              | $ | 2,484 |  |   | $ | 2,430 |  |   | $ | 2,429 |  |   | $ | 7,286 |  |
| Provision for uncollectible accounts                   | (118 | ) |   | (109 | ) |   | (109 | ) |   | (334 | ) |
| Net patient service operating revenues                 | 2,366 |  |   | 2,320 |  |   | 2,320 |  |   | 6,952 |  |
| Other revenues                                         | 5 |  |   | 5 |  |   | 4 |  |   | 15 |  |
| Total net operating revenues                           | 2,370 |  |   | 2,325 |  |   | 2,324 |  |   | 6,967 |  |
| Operating expenses:                                    |   |   |   |   |   |   |   |
| Patient care costs                                     | 1,607 |  |   | 1,561 |  |   | 1,565 |  |   | 4,715 |  |
| General and administrative                             | 197 |  |   | 189 |  |   | 188 |  |   | 574 |  |
| Depreciation and amortization                          | 132 |  |   | 130 |  |   | 123 |  |   | 387 |  |
| Equity investment income                               | (8 | ) |   | (5 | ) |   | (4 | ) |   | (20 | ) |
| Gain on settlement, net                                | — |  |   | — |  |   | — |  |   | (527 | ) |
| Total operating expenses                               | 1,928 |  |   | 1,875 |  |   | 1,872 |  |   | 5,129 |  |
| Segment operating income                               | $ | 443 |  |   | $ | 450 |  |   | $ | 452 |  |   | $ | 1,838 |  |
| Reconciliation for non-GAAP measure:                   |   |   |   |   |   |   |   |
| Gain on settlement, net                                | — |  |   | — |  |   | — |  |   | (527 | ) |
| Equity investment income related to gain on settlement | — |  |   | — |  |   | — |  |   | (3 | ) |
| Adjusted segment operating income(1)                   | $ | 443 |  |   | $ | 450 |  |   | $ | 452 |  |   | $ | 1,308 |  |
|                                                   |   |   |   |   |   |   |   |
| DMG                                                    |   |   |   |   |   |   |   |
| Revenue:                                               |   |   |   |   |   |   |   |
| DMG capitated revenues                                 | $ | 976 |  |   | $ | 987 |  |   | $ | 846 |  |   | $ | 2,853 |  |
| Patient services revenues                              | 192 |  |   | 195 |  |   | 173 |  |   | 572 |  |
| Provision for uncollectible accounts                   | (4 | ) |   | (6 | ) |   | (6 | ) |   | (16 | ) |
| Net patient service operating revenues                 | 188 |  |   | 190 |  |   | 167 |  |   | 556 |  |
| Other revenues                                         | 15 |  |   | 19 |  |   | 15 |  |   | 53 |  |
| Total net operating revenues                           | 1,178 |  |   | 1,196 |  |   | 1,028 |  |   | 3,461 |  |
| Operating expenses:                                    |   |  |   |   |  |   |   |  |   |   |
| Patient care costs                                     | 995 |  |   | 983 |  |   | 824 |  |   | 2,870 |  |
| General and administrative                             | 127 |  |   | 120 |  |   | 121 |  |   | 376 |  |
| Depreciation and amortization                          | 61 |  |   | 60 |  |   | 53 |  |   | 178 |  |
| Goodwill and asset impairment charges                  | 601 |  |   | 51 |  |   | — |  |   | 652 |  |
| Gain on changes in ownership interests, net            | (17 | ) |   | — |  |   | — |  |   | (17 | ) |
| Equity investment income                               | — |  |   | (4 | ) |   | (3 | ) |   | (8 | ) |
| Total operating expenses                               | 1,766 |  |   | 1,209 |  |   | 995 |  |   | 4,050 |  |
| Segment operating (loss) income                        | $ | (588 | ) |   | $ | (13 | ) |   | $ | 33 |  |   | $ | (588 | ) |
| Reconciliation for non-GAAP measure:                   |   |   |   |   |   |   |   |
| Goodwill impairment charges                            | 601 |  |   | 51 |  |   | — |  |   | 652 |  |
| Gain on Magan acquisition                              | (17 | ) |   | — |  |   | — |  |   | (17 | ) |
| Restructuring charges                                  | 10 |  |   | — |  |   | — |  |   | 10 |  |
| Accruals for legal matters                             | (11 | ) |   | (4 | ) |   | — |  |   | (15 | ) |
| Adjusted segment operating (loss) income(1)            | $ | (5 | ) |   | $ | 34 |  |   | $ | 33 |  |   | $ | 41 |  |

----

|                                                                  |
|------------------------------------------------------------------|
|                                                                  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                                             | Three months ended |   | Nine months ended September 30, 2017 |
|                                                             | September 30,2017 |   | June 30,2017 |   | September 30,2016 |   |
| 5. U.S. Dialysis and Related Lab Services Business Metrics:      |   |   |   |   |   |   |   |
| Volume                                                           |   |   |   |   |   |   |   |
| Treatments                                                       | 7,186,280 |  |   | 7,035,894 |  |   | 6,887,992 |  |   | 21,026,558 |  |
| Number of treatment days                                         | 79.0 |  |   | 78.0 |  |   | 79.0 |  |   | 234.0 |  |
| Treatments per day                                               | 90,966 |  |   | 90,204 |  |   | 87,190 |  |   | 89,857 |  |
| Per day year over year increase                                  | 4.3 |  % |   | 4.3 |  % |   | 4.2 | % |   | 4.1 |  % |
| Normalized non-acquired treatment growth year over year          | 3.3 |  % |   | 3.6 |  % |   | 4.4 | % |   | 3.5 |  % |
| Operating revenues before provision for uncollectible accounts   |   |   |   |   |   |   |   |
| Dialysis and related lab services revenue per treatment          | $ | 345.61 |  |   | $ | 345.32 |  |   | $ | 352.62 |  |   | $ | 346.51 |  |
| Per treatment increase (decrease) from previous quarter          | 0.1 |  % |   | (1.0 | )% |   | 0.5 | % |   |   |
| Per treatment (decrease) increase from previous year             | (2.0 | )% |   | (1.6 | )% |   | 1.3 | % |   | (1.4 | )% |
| Percent of consolidated net revenues                             | 59.8 |  % |   | 59.3 |  % |   | 61.9 | % |   | 59.9 |  % |
| Expenses                                                         |   |   |   |   |   |   |   |
| Patient care costs                                               |   |   |   |   |   |   |   |
| Percent of total segment operating net revenues                  | 67.8 |  % |   | 67.1 |  % |   | 67.3 | % |   | 67.7 |  % |
| Per treatment                                                    | $ | 223.58 |  |   | $ | 221.82 |  |   | $ | 227.16 |  |   | $ | 224.25 |  |
| Per treatment increase (decrease) from previous quarter          | 0.8 |  % |   | (2.5 | )% |   | 1.1 | % |   |   |
| Per treatment (decrease) increase from previous year             | (1.6 | )% |   | (1.3 | )% |   | 2.8 | % |   | (0.7 | )% |
| General and administrative expenses                              |   |   |   |   |   |   |   |
| Percent of total segment operating net revenues                  | 8.3 |  % |   | 8.1 |  % |   | 8.1 | % |   | 8.2 |  % |
| Per treatment                                                    | $ | 27.36 |  |   | $ | 26.85 |  |   | $ | 27.36 |  |   | $ | 27.28 |  |
| Per treatment increase (decrease) from previous quarter          | 1.9 |  % |   | (2.9 | )% |   | — | % |   |   |
| Per treatment (decrease) increase from previous year             | — |  % |   | (1.9 | )% |   | 6.1 | % |   | 0.2 |  % |
| Accounts receivable                                              |   |   |   |   |   |   |   |
| Net receivables                                                  | $ | 1,532 |  |   | $ | 1,420 |  |   | $ | 1,306 |  |   |   |
| DSO                                                              | 60 |  |   | 56 |  |   | 52 |  |   |   |
| Provision for uncollectible accounts as a percentage of revenues | 4.75 |  % |   | 4.50 |  % |   | 4.50 | % |   | 4.59 |  % |
|                                                             |   |   |   |   |   |   |   |
| 6. DMG Business Metrics:                                         |   |   |   |   |   |   |   |
| Capitated membership                                             |   |   |   |   |   |   |   |
| Total members                                                    | 765,500 |  |   | 726,000 |  |   | 749,900 |  |   |   |
| Total member months                                              |   |   |   |   |   |   |   |
| Senior                                                           | 953,300 |  |   | 918,200 |  |   | 914,000 |  |   | 2,791,800 |  |
| Commercial                                                       | 1,059,200 |  |   | 983,000 |  |   | 1,026,300 |  |   | 3,038,100 |  |
| Medicaid                                                         | 287,100 |  |   | 291,200 |  |   | 326,500 |  |   | 883,400 |  |
| Total member months                                              | 2,299,600 |  |   | 2,192,400 |  |   | 2,266,800 |  |   | 6,713,300 |  |
| Capitated revenues by sources                                    |   |   |   |   |   |   |   |
| Senior revenues                                                  | $ | 738 |  |   | $ | 753 |  |   | $ | 634 |  |   | $ | 2,151 |  |
| Commercial revenues                                              | 201 |  |   | 194 |  |   | 165 |  |   | 583 |  |
| Medicaid revenues                                                | 36 |  |   | 41 |  |   | 47 |  |   | 119 |  |
| Total capitated revenues                                         | $ | 976 |  |   | $ | 987 |  |   | $ | 846 |  |   | $ | 2,853 |  |

----

|                                                                                                                            |
|----------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                            |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                                                                                                       | Three months ended |   | Nine months ended September 30, 2017 |
|                                                                                                                       | September 30,2017 |   | June 30,2017 |   | September 30,2016 |   |
| 6. DMG Business Metrics: (continued)                                                                                       |   |   |   |   |   |   |   |
| Other                                                                                                                      |   |   |   |   |   |   |   |
| Total care dollars under management(1)                                                                                     | $ | 1,355 |  |   | $ | 1,355 |  |   | $ | 1,311 |  |   | $ | 4,064 |  |
| Ratio of operating (loss) income to total care dollars under management(1)                                                 | (43.4 | )% |   | (1.0 | )% |   | 2.5 | % |   | (14.5 | )% |
| Ratio of adjusted operating (loss) income to total care dollars under management(1)(6)                                     | (0.4 | )% |   | 2.5 |  % |   | 2.5 | % |   | 1.0 |  % |
|                                                                                                                       |   |   |   |   |   |   |   |
| 7. Cash Flow:                                                                                                              |   |   |   |   |   |   |   |
| Operating cash flow                                                                                                        | $ | 553.1 |  |   | $ | 146.3 |  |   | $ | 535.6 |  |   | $ | 1,564.5 |  |
| Operating cash flow, last twelve months                                                                                    | $ | 2,046.7 |  |   | $ | 2,029.2 |  |   | $ | 1,917.9 |  |   |   |
| Free cash flow(1)                                                                                                          | $ | 405.3 |  |   | $ | 17.9 |  |   | $ | 386.2 |  |   | $ | 1,157.0 |  |
| Free cash flow, last twelve months(1)                                                                                      | $ | 1,486.4 |  |   | $ | 1,467.3 |  |   | $ | 1,339.1 |  |   |   |
| Capital expenditures:                                                                                                      |   |   |   |   |   |   |   |
| Routine maintenance/IT/other                                                                                               | $ | 98.4 |  |   | $ | 55.6 |  |   | $ | 98.5 |  |   | $ | 242.1 |  |
| Development and relocations                                                                                                | $ | 142.5 |  |   | $ | 128.8 |  |   | $ | 118.1 |  |   | $ | 397.7 |  |
| Acquisition expenditures                                                                                                   | $ | 106.7 |  |   | $ | 542.6 |  |   | $ | 24.0 |  |   | $ | 726.5 |  |
|                                                                                                                       |   |   |   |   |   |   |   |
| 8. Debt and Capital Structure:                                                                                             |   |   |   |   |   |   |   |
| Total debt(3)                                                                                                              | $ | 9,166 |  |   | $ | 9,165 |  |   | $ | 9,209 |  |   |   |
| Net debt, net of cash and cash equivalents(3)                                                                              | $ | 8,320 |  |   | $ | 8,453 |  |   | $ | 8,295 |  |   |   |
| Leverage ratio (see calculation on page 16)                                                                                | 3.45x |  |   | 3.38x |  |   | 2.98x |  |   |   |
| Overall weighted average effective interest rate during the quarter                                                        | 4.77 |  % |   | 4.69 |  % |   | 4.42 | % |   |   |
| Overall weighted average effective interest rate at end of the quarter                                                     | 4.78 |  % |   | 4.76 |  % |   | 4.49 | % |   |   |
| Weighted average effective interest rate on the senior secured credit facilities at end of the quarter                     | 4.22 |  % |   | 4.20 |  % |   | 3.61 | % |   |   |
| Fixed and economically fixed interest rates as a percentage of our total debt                                              | 54 |  % |   | 53 |  % |   |       53%(4) |  |   |   |
| Fixed and economically fixed interest rates, including our interest rate cap agreements, as a percentage of our total debt | 92 |  % |   | 91 |  % |   |       91%(4) |  |   |   |

|     |                                                                                                                                                                                                                                                                      |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (1) | These are non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures to their most comparable measure calculated and presented in accordance with GAAP, and for a definition of adjusted amounts, see attached reconciliation schedules. |

|     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Consolidated percentages of revenues are comprised of the dialysis and related lab services business, DMG’s business and other ancillary services and strategic initiatives. General and administrative expenses includes certain corporate support and long-term incentive compensation, as well as restructuring charges for the three and nine months ended September 30, 2017, estimated accruals for certain legal matters for the three months ended September 30, 2017 and June 30, 2017 and the nine months ended September 30, 2017, and an adjustment to reduce a receivable associated with the DMG acquisition escrow provision relating to an income tax item for the three months ended September 30, 2016. |

|     |                                                                                                                                                                                                                                                                             |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (3) | The reported balance sheet amounts at September 30, 2017, June 30, 2017, and September 30, 2016, exclude $67.9 million, $71.9 million and $83.9 million, respectively, of a debt discount associated with our Term Loan B and other deferred financing costs. |

|     |                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (4) | The Term Loan B is subject to a LIBOR floor of 0.75%. At September 30, 2017 and June 30, 2017, the actual LIBOR-based variable component of our interest rate exceeded 0.75% on the Term Loan B, and was subject to LIBOR-based interest rate volatility on the LIBOR variable component of our interest rate on all of the Term Loan B. However, we are limited to a maximum rate of 3.50% on the |

----

|     |                                                                                                                      |
|-----|----------------------------------------------------------------------------------------------------------------------|
| (5) | Adjusted operating income margin is a calculation of adjusted operating income divided by consolidated net revenues. |

|     |                                                                                                                                                                         |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (6) | Ratio of adjusted operating income to total care dollars under management is a calculation of adjusted operating income divided by total care dollars under management. |

----

|                                                                                                                        |
|------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                        |  |  |  |
|                                                                                                                   | Rolling twelve months endedSeptember 30, 2017 |
| Net income attributable to DaVita Inc.                                                                                 | $ | 517,949 |  |
| Income taxes                                                                                                           | 365,807 |  |
| Interest expense                                                                                                       | 391,181 |  |
| Depreciation and amortization                                                                                          | 782,304 |  |
| Goodwill and other asset impairment charges                                                                            | 744,931 |  |
| Noncontrolling interests and equity investment income, net                                                             | 180,449 |  |
| Stock-settled stock-based compensation                                                                                 | 37,098 |  |
| Gain on changes in ownership interest, net                                                                             | (23,402 | ) |
| Gain on settlement, net                                                                                                | (529,504 | ) |
| Other                                                                                                                  | (16,186 | ) |
| “Consolidated EBITDA”                                                                                      | $ | 2,450,627 |  |
|                                                                                                                   |   |
|                                                                                                                   | September 30, 2017 |
| Total debt, excluding debt discount and other deferred financing costs of $67.9 million                                | $ | 9,166,430 |  |
| Letters of credit issued                                                                                               | 94,779 |  |
|                                                                                                                   | $ | 9,261,209 |  |
| Less: Cash and cash equivalents including short-term investments (excluding DMG’s physician owned entities cash) | (804,698 | ) |
| Consolidated net debt                                                                                                  | $ | 8,456,511 |  |
| Last twelve months “Consolidated EBITDA”                                                                   | $ | 2,450,627 |  |
| Leverage ratio                                                                                                         | 3.45x |  |

----

|                                                                                 |
|---------------------------------------------------------------------------------|
|                                                                                 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                                                            | Three months ended |   | Nine months ended |
|                                                                            | September 30,2017 |   | June 30,2017 |   | September 30,2016 |   | September 30,2017 |   | September 30,2016 |
| Net (loss) income attributable to DaVita Inc.                                   | $ | (214,476 | ) |   | $ | 127,001 |  |   | $ | 571,332 |  |   | $ | 360,222 |  |   | $ | 722,148 |  |
| Goodwill impairment charges                                                     | 601,040 |  |   | 61,117 |  |   | — |  |   | 686,355 |  |   | 253,000 |  |
| Equity investment loss related to APAC JV goodwill impairment                   | 6,293 |  |   | — |  |   | — |  |   | 6,293 |  |   | — |  |
| Impairment of assets                                                            | — |  |   | — |  |   | — |  |   | 15,168 |  |   | — |  |
| Restructuring charges                                                           | 11,269 |  |   | — |  |   | — |  |   | 11,269 |  |   | — |  |
| Equity investment loss related to restructuring charges                         | 1,000 |  |   | — |  |   | — |  |   | 1,000 |  |   | — |  |
| Gain on settlement, net                                                         | — |  |   | — |  |   | — |  |   | (526,827 | ) |   | — |  |
| Equity investment income related to gain on settlement                          | — |  |   | — |  |   | — |  |   | (2,677 | ) |   | — |  |
| Gain on Magan acquisition                                                       | (17,129 | ) |   | — |  |   | — |  |   | (17,129 | ) |   | — |  |
| Gain on APAC JV ownership changes                                               | — |  |   | — |  |   | (374,374 | ) |   | (6,273 | ) |   | (374,374 | ) |
| Accruals for legal matters                                                      | (11,100 | ) |   | (3,600 | ) |   | — |  |   | (14,700 | ) |   | 16,000 |  |
| Gain on sale of Tandigm ownership interests                                     | — |  |   | — |  |   | — |  |   | — |  |   | (40,280 | ) |
| Loss on sale of DMG Arizona                                                     | — |  |   | — |  |   | — |  |   | — |  |   | 10,489 |  |
| Reduction in a receivable associated with the DMG  acquisition escrow provision | — |  |   | — |  |   | 27,040 |  |   | — |  |   | 27,040 |  |
| Noncontrolling interests associated with adjustments:                           |   |   |   |   |   |   |   |   |   |
| Goodwill impairment charges                                                     | — |  |   | (2,985 | ) |   | — |  |   | (9,865 | ) |   | — |  |
| Gain on settlement, net                                                         | — |  |   | — |  |   | — |  |   | 24,029 |  |   | — |  |
| Related income tax                                                              | (221,839 | ) |   | (2,850 | ) |   | (27,040 | ) |   | (39,527 | ) |   | (16,626 | ) |
| Adjusted net income attributable to DaVita Inc.                                 | $ | 155,058 |  |   | $ | 178,683 |  |   | $ | 196,958 |  |   | $ | 487,338 |  |   | $ | 597,397 |  |

----

|                                                                                |
|--------------------------------------------------------------------------------|
|                                                                                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                                                           | Three months ended |   | Nine months ended |
|                                                                           | September 30,2017 |   | June 30,2017 |   | September 30,2016 |   | September 30,2017 |   | September 30,2016 |
| Diluted net (loss) income per share attributable to DaVita Inc.                | $ | (1.14 | ) |   | $ | 0.65 |  |   | $ | 2.76 |  |   | $ | 1.86 |  |   | $ | 3.48 |  |
| Goodwill impairment charges                                                    | 3.18 |  |   | 0.32 |  |   | — |  |   | 3.55 |  |   | 1.22 |  |
| Equity investment loss related to APAC JV goodwill impairment                  | 0.03 |  |   | — |  |   | — |  |   | 0.03 |  |   | — |  |
| Impairment of assets                                                           | — |  |   | — |  |   | — |  |   | 0.08 |  |   | — |  |
| Restructuring charges                                                          | 0.05 |  |   | — |  |   | — |  |   | 0.05 |  |   | — |  |
| Equity investment loss related to restructuring charges                        | 0.01 |  |   | — |  |   | — |  |   | 0.01 |  |   | — |  |
| Gain on settlement, net                                                        | — |  |   | — |  |   | — |  |   | (2.72 | ) |   | — |  |
| Equity investment income related to gain on settlement                         | — |  |   | — |  |   | — |  |   | (0.01 | ) |   | — |  |
| Gain on Magan acquisition                                                      | (0.09 | ) |   | — |  |   | — |  |   | (0.09 | ) |   | — |  |
| Gain on APAC JV ownership changes                                              | — |  |   | — |  |   | (1.81 | ) |   | (0.03 | ) |   | (1.81 | ) |
| Accruals for legal matters                                                     | (0.06 | ) |   | (0.02 | ) |   | — |  |   | (0.08 | ) |   | 0.08 |  |
| Gain on sale of Tandigm ownership interests                                    | — |  |   | — |  |   | — |  |   | — |  |   | (0.19 | ) |
| Loss on sale of DMG Arizona                                                    | — |  |   | — |  |   | — |  |   | — |  |   | 0.05 |  |
| Reduction in a receivable associated with the DMG acquisition escrow provision | — |  |   | — |  |   | 0.13 |  |   | — |  |   | 0.13 |  |
| Noncontrolling interests associated with adjustments                           |   |   |   |   |   |   |   |   | — |  |
| Goodwill impairment charges                                                    | — |  |   | (0.02 | ) |   | — |  |   | (0.05 | ) |   | — |  |
| Gain on settlement, net                                                        | — |  |   | — |  |   | — |  |   | 0.12 |  |   | — |  |
| Related income tax                                                             | (1.17 | ) |   | (0.01 | ) |   | (0.13 | ) |   | (0.20 | ) |   | (0.08 | ) |
| Adjusted diluted net income per share attributable to DaVita Inc.              | $ | 0.81 |  |   | $ | 0.92 |  |   | $ | 0.95 |  |   | $ | 2.52 |  |   | $ | 2.88 |  |

----

|                                                                                             |
|---------------------------------------------------------------------------------------------|
|                                                                                             |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                                                                        | Three months ended |   | Nine months ended |
|                                                                                        | September 30,2017 |   | June 30,2017 |   | September 30,2016 |   | September 30,2017 |   | September 30,2016 |
| Adjusted net income per share attributable to DaVita Inc.                                   | $ | 155,058 |  |   | $ | 178,683 |  |   | $ | 196,958 |  |   | $ | 487,338 |  |   | $ | 597,397 |  |
| Add: Amortization of intangible assets associated with           acquisitions for:          |   |   |   |   |   |   |   |   |   |
| Dialysis and ancillary operations                                                           | 4,408 |  |   | 3,818 |  |   | 3,588 |  |   | 11,951 |  |   | 11,071 |  |
| DMG operations                                                                              | 44,729 |  |   | 44,274 |  |   | 39,303 |  |   | 132,958 |  |   | 115,677 |  |
| Less: Related income tax                                                                    | (18,795 | ) |   | (18,996 | ) |   | (17,156 | ) |   | (56,863 | ) |   | (49,380 | ) |
|                                                                                        | $ | 185,400 |  |   | $ | 207,779 |  |   | $ | 222,693 |  |   | $ | 575,384 |  |   | $ | 674,765 |  |
|                                                                                        |   |   |   |   |   |   |   |   |   |
| Adjusted diluted net income per share attributable to DaVita Inc.                           | $ | 0.81 |  |   | $ | 0.92 |  |   | $ | 0.95 |  |   | $ | 2.52 |  |   | $ | 2.88 |  |
| Add: Amortization of intangible assets per share          associated with acquisitions for: |   |   |   |   |   |   |   |   |   |
| Dialysis and ancillary operations                                                           | 0.02 |  |   | 0.02 |  |   | 0.02 |  |   | 0.06 |  |   | 0.05 |  |
| DMG operations                                                                              | 0.24 |  |   | 0.23 |  |   | 0.19 |  |   | 0.69 |  |   | 0.56 |  |
| Tax effect of adjustments                                                                   | (0.10 | ) |   | (0.10 | ) |   | (0.08 | ) |   | (0.30 | ) |   | (0.24 | ) |
| Adjusted net income per share attributable to DaVita Inc.                                   | $ | 0.97 |  |   | $ | 1.07 |  |   | $ | 1.08 |  |   | $ | 2.97 |  |   | $ | 3.25 |  |

----

|                                                                                |
|--------------------------------------------------------------------------------|
|                                                                                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                                                           | Three months ended |   | Nine months ended |
|                                                                           | September 30,2017 |   | June 30,2017 |   | September 30,2016 |   | September 30,2017 |   | September 30,2016 |
| Consolidated:                                                                  |   |   |   |   |   |   |   |   |   |
| Operating (loss) income                                                        | $ | (192,523 | ) |   | $ | 378,316 |  |   | $ | 819,156 |  |   | $ | 1,074,029 |  |   | $ | 1,513,115 |  |
| Goodwill impairment charges                                                    | 601,040 |  |   | 61,117 |  |   | — |  |   | 686,355 |  |   | 253,000 |  |
| Equity investment loss related to APAC JV goodwill impairment                  | 6,293 |  |   | — |  |   | — |  |   | 6,293 |  |   | — |  |
| Impairment of assets                                                           | — |  |   | — |  |   | — |  |   | 15,168 |  |   | — |  |
| Restructuring charges                                                          | 11,269 |  |   | — |  |   | — |  |   | 11,269 |  |   | — |  |
| Equity investment loss related to restructuring charges                        | 1,000 |  |   | — |  |   | — |  |   | 1,000 |  |   | — |  |
| Gain on settlement, net                                                        | — |  |   | — |  |   | — |  |   | (526,827 | ) |   | — |  |
| Equity investment income related to gain on settlement                         | — |  |   | — |  |   | — |  |   | (2,677 | ) |   | — |  |
| Gain on Magan acquisition                                                      | (17,129 | ) |   | — |  |   | — |  |   | (17,129 | ) |   | — |  |
| Gain on APAC JV ownership changes                                              | — |  |   | — |  |   | (374,374 | ) |   | (6,273 | ) |   | (374,374 | ) |
| Accruals for legal matters                                                     | (11,100 | ) |   | (3,600 | ) |   | — |  |   | (14,700 | ) |   | 16,000 |  |
| Gain on sale of Tandigm ownership interests                                    | — |  |   | — |  |   | — |  |   | — |  |   | (40,280 | ) |
| Loss on sale of DMG Arizona                                                    | — |  |   | — |  |   | — |  |   | — |  |   | 10,489 |  |
| Reduction in a receivable associated with the DMG acquisition escrow provision | — |  |   | — |  |   | 27,040 |  |   | — |  |   | 27,040 |  |
| Adjusted operating income                                                      | $ | 398,850 |  |   | $ | 435,833 |  |   | $ | 471,822 |  |   | $ | 1,226,508 |  |   | $ | 1,404,990 |  |

----

|                                                                                |
|--------------------------------------------------------------------------------|
|                                                                                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                                                           | Three months ended |   | Nine months ended |
|                                                                           | September 30,2017 |   | June 30,2017 |   | September 30,2016 |   | September 30,2017 |   | September 30,2016 |
| Kidney Care:                                                                   |   |   |   |   |   |   |   |   |   |
| U.S. dialysis and related lab services:                                        |   |   |   |   |   |   |   |   |   |
| Segment operating income                                                       | $ | 442,777 |  |   | $ | 450,472 |  |   | $ | 452,187 |  |   | $ | 1,837,989 |  |   | $ | 1,341,432 |  |
| Gain on settlement, net                                                        | — |  |   | — |  |   | — |  |   | (526,827 | ) |   | — |  |
| Equity investment income related to gain on settlement                         | — |  |   | — |  |   | — |  |   | (2,677 | ) |   | — |  |
| Adjusted operating income                                                      | 442,777 |  |   | 450,472 |  |   | 452,187 |  |   | 1,308,485 |  |   | 1,341,432 |  |
| Other - Ancillary services and strategic initiatives:                          |   |   |   |   |   |   |   |   |   |
| U.S. ancillary services and strategic initiatives                              |   |   |   |   |   |   |   |   |   |
| Segment operating loss                                                         | (19,245 | ) |   | (35,545 | ) |   | (5,935 | ) |   | (107,817 | ) |   | (7,024 | ) |
| Goodwill impairment charges                                                    | — |  |   | 10,498 |  |   | — |  |   | 34,696 |  |   | — |  |
| Impairment of assets                                                           | — |  |   | — |  |   | — |  |   | 15,168 |  |   | — |  |
| Adjusted operating loss                                                        | (19,245 | ) |   | (25,047 | ) |   | (5,935 | ) |   | (57,953 | ) |   | (7,024 | ) |
| International dialysis                                                         |   |   |   |   |   |   |   |   |   |
| Segment operating (loss) income                                                | (17,273 | ) |   | (12,700 | ) |   | 367,838 |  |   | (35,166 | ) |   | 345,183 |  |
| Equity investment loss related to APAC JV goodwill impairment                  | 6,293 |  |   | — |  |   | — |  |   | 6,293 |  |   | — |  |
| Restructuring charges                                                          | 1,700 |  |   | — |  |   | — |  |   | 1,700 |  |   | — |  |
| Equity investment loss related to restructuring charges                        | 1,000 |  |   | — |  |   | — |  |   | 1,000 |  |   | — |  |
| Gain on APAC JV ownership changes                                              | — |  |   | — |  |   | (374,374 | ) |   | (6,273 | ) |   | (374,374 | ) |
| Adjusted operating loss                                                        | (8,279 | ) |   | (12,700 | ) |   | (6,535 | ) |   | (32,446 | ) |   | (29,191 | ) |
| Adjusted operating loss                                                        | (27,524 | ) |   | (37,747 | ) |   | (12,471 | ) |   | (90,399 | ) |   | (36,215 | ) |
| Corporate administrative support:                                              |   |   |   |   |   |   |   |   |   |
| Segment operating loss                                                         | (10,965 | ) |   | (11,031 | ) |   | (28,028 | ) |   | (32,587 | ) |   | (40,366 | ) |
| Reduction in a receivable associated with the DMG acquisition escrow provision | — |  |   | — |  |   | 27,040 |  |   | — |  |   | 27,040 |  |
| Adjusted operating loss                                                        | (10,965 | ) |   | (11,031 | ) |   | (988 | ) |   | (32,587 | ) |   | (13,326 | ) |
| Kidney Care adjusted operating income                                          | 404,287 |  |   | 401,694 |  |   | 438,728 |  |   | 1,185,499 |  |   | 1,291,891 |  |
| DMG:                                                                           |   |   |   |   |   |   |   |   |   |
| Segment operating (loss) income                                                | (587,817 | ) |   | (12,880 | ) |   | 33,094 |  |   | (588,389 | ) |   | (126,110 | ) |
| Goodwill impairment charges                                                    | 601,040 |  |   | 50,619 |  |   | — |  |   | 651,659 |  |   | 253,000 |  |
| Restructuring charges                                                          | 9,569 |  |   | — |  |   | — |  |   | 9,569 |  |   | — |  |
| Gain on Magan acquisition                                                      | (17,129 | ) |   | — |  |   | — |  |   | (17,129 | ) |   | — |  |
| Accruals for legal matters                                                     | (11,100 | ) |   | (3,600 | ) |   | — |  |   | (14,700 | ) |   | 16,000 |  |
| Gain on sale of Tandigm ownership interests                                    | — |  |   | — |  |   | — |  |   | — |  |   | (40,280 | ) |
| Loss on sale of DMG Arizona                                                    | — |  |   | — |  |   | — |  |   | — |  |   | 10,489 |  |
| DMG adjusted operating (loss) income                                           | (5,438 | ) |   | 34,139 |  |   | 33,094 |  |   | 41,009 |  |   | 113,099 |  |
| Consolidated adjusted operating income                                         | $ | 398,850 |  |   | $ | 435,833 |  |   | $ | 471,822 |  |   | $ | 1,226,508 |  |   | $ | 1,404,990 |  |

----

|                                   |
|-----------------------------------|
|                                   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                              | Three months ended |   | Nine months ended September 30, 2017 |
|                              | September 30,2017 |   | June 30,2017 |   | September 30,2016 |   |
| (Loss) income before income taxes | $ | (297,776 | ) |   | $ | 275,607 |  |   | $ | 716,451 |  |   | $ | 765,881 |  |
| Income tax (benefit) expense      | $ | (125,742 | ) |   | $ | 113,982 |  |   | $ | 104,301 |  |   | $ | 276,005 |  |
| Effective income tax rate         | 42.2 | % |   | 41.4 | % |   | 14.6 | % |   | 36.0 | % |

|                                                                                                           |
|-----------------------------------------------------------------------------------------------------------|
|                                                                                                           |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                                                                                      | Three months ended |   | Nine months ended September 30, 2017 |
|                                                                                                      | September 30,2017 |   | June 30,2017 |   | September 30,2016 |   |
| (Loss) income before income taxes                                                                         | $ | (297,776 | ) |   | $ | 275,607 |  |   | $ | 716,451 |  |   | $ | 765,881 |  |
| Less:   Noncontrolling owners’ income primarily attributable             to non-tax paying entities | (42,484 | ) |   | (34,906 | ) |   | (40,909 | ) |   | (130,043 | ) |
| (Loss) income before income taxes attributable to DaVita Inc.                                             | $ | (340,260 | ) |   | $ | 240,701 |  |   | $ | 675,542 |  |   | $ | 635,838 |  |
|                                                                                                      |   |   |   |   |   |   |   |
| Income tax (benefit) expense                                                                              | $ | (125,742 | ) |   | $ | 113,982 |  |   | $ | 104,301 |  |   | $ | 276,005 |  |
| Less: Income tax attributable to noncontrolling interests                                                 | (42 | ) |   | (282 | ) |   | (91 | ) |   | (389 | ) |
| Income tax (benefit) expense attributable to DaVita Inc.                                                  | $ | (125,784 | ) |   | $ | 113,700 |  |   | $ | 104,210 |  |   | $ | 275,616 |  |
|                                                                                                      |   |   |   |   |   |   |   |
| Effective income tax rate attributable to DaVita Inc.                                                     | 37.0 | % |   | 47.2 | % |   | 15.4 | % |   | 43.3 | % |

----

|                                                                                       |
|---------------------------------------------------------------------------------------|
|                                                                                       |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                                                                  | Three months ended |   | Nine months ended September 30, 2017 |
| September 30,2017                                                                     |   | June 30,2017 |   | September 30,2016 |   |
| (Loss) income before income taxes                                                     | $ | (297,776 | ) |   | $ | 275,607 |  |   | $ | 716,451 |  |   | $ | 765,881 |  |
| Goodwill impairment charges                                                           | 601,040 |  |   | 61,117 |  |   | — |  |   | 686,355 |  |
| Equity investment loss related to APAC JV goodwill impairment                         | 6,293 |  |   | — |  |   | — |  |   | 6,293 |  |
| Impairment of assets                                                                  | — |  |   | — |  |   | — |  |   | 15,168 |  |
| Restructuring charges                                                                 | 11,269 |  |   | — |  |   | — |  |   | 11,269 |  |
| Equity investment loss related to restructuring charges                               | 1,000 |  |   | — |  |   | — |  |   | 1,000 |  |
| Gain on settlement, net                                                               | — |  |   | — |  |   | — |  |   | (526,827 | ) |
| Equity investment income related to gain on settlement                                | — |  |   | — |  |   | — |  |   | (2,677 | ) |
| Gain on Magan acquisition                                                             | (17,129 | ) |   | — |  |   | — |  |   | (17,129 | ) |
| Gain on APAC JV ownership changes                                                     | — |  |   | — |  |   | (374,374 | ) |   | (6,273 | ) |
| Accrual for legal matters                                                             | (11,100 | ) |   | (3,600 | ) |   | — |  |   | (14,700 | ) |
| Reduction in a receivable associated with the DMG acquisition escrow provision        | — |  |   | — |  |   | 27,040 |  |   | — |  |
| Noncontrolling owners’ income primarily attributable to non-tax paying entities | (42,484 | ) |   | (34,906 | ) |   | (40,909 | ) |   | (130,043 | ) |
| Noncontrolling interests associated with adjustments                                  |   |   |   |   |   |   |   |
| Goodwill impairment charges                                                           | — |  |   | (2,985 | ) |   | — |  |   | (9,865 | ) |
| Gain on settlement, net                                                               | — |  |   | — |  |   | — |  |   | 24,029 |  |
| Adjusted income before income taxes attributable to DaVita Inc.                       | $ | 251,113 |  |   | $ | 295,233 |  |   | $ | 328,208 |  |   | $ | 802,481 |  |
| Income tax (benefit) expense                                                          | $ | (125,742 | ) |   | $ | 113,982 |  |   | $ | 104,301 |  |   | $ | 276,005 |  |
| Add income tax related to:                                                            |   |   |   |   |   |   |   |
| Goodwill impairment charges                                                           | 218,134 |  |   | 2,850 |  |   | — |  |   | 227,552 |  |
| Impairment of assets                                                                  | — |  |   | — |  |   | — |  |   | 5,752 |  |
| Restructuring charges                                                                 | 3,705 |  |   | — |  |   | — |  |   | 3,705 |  |
| Reduction in a receivable associated with the DMG acquisition escrow provision        | — |  |   | — |  |   | 27,040 |  |   | — |  |
| Less income tax related to:                                                           |   |   |   |   |   |   |   |
| Gain on settlement, net                                                               | — |  |   | — |  |   | — |  |   | (197,482 | ) |
| Noncontrolling interests                                                              | (42 | ) |   | (282 | ) |   | (91 | ) |   | (389 | ) |
| Adjusted income tax attributable to DaVita Inc.                                       | $ | 96,055 |  |   | $ | 116,550 |  |   | $ | 131,250 |  |   | $ | 315,143 |  |
| Adjusted effective income tax rate attributable to DaVita Inc.                        | 38.3 | % |   | 39.5 | % |   | 40.0 | % |   | 39.3 | % |

----

|                                                                                |
|--------------------------------------------------------------------------------|
|                                                                                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                                                           | Three months ended |   | Nine months ended September 30, 2017 |
|                                                                           | September 30,2017 |   | June 30,2017 |   | September 30,2016 |   |
| Cash provided by operating activities                                          | $ | 553,095 |  |   | $ | 146,270 |  |   | $ | 535,623 |  |   | $ | 1,564,539 |  |
| Less:  Distributions to noncontrolling interests                               | (49,388 | ) |   | (72,759 | ) |   | (50,919 | ) |   | (165,463 | ) |
| Cash provided by operating activities attributable to DaVita Inc.              | 503,707 |  |   | 73,511 |  |   | 484,704 |  |   | 1,399,076 |  |
| Less: Expenditures for routine maintenance and information          technology | (98,433 | ) |   | (55,577 | ) |   | (98,464 | ) |   | (242,122 | ) |
| Free cash flow                                                                 | $ | 405,274 |  |   | $ | 17,934 |  |   | $ | 386,240 |  |   | $ | 1,156,954 |  |

|                                                                       |
|-----------------------------------------------------------------------|
|                                                                       |  |  |  |  |  |  |  |  |  |  |  |
|                                                                  | Rolling 12-Month Period |
|                                                                  | September 30,2017 |   | June 30,2017 |   | September 30,2016 |
| Cash provided by operating activities                                 | $ | 2,046,721 |  |   | $ | 2,029,249 |  |   | $ | 1,917,935 |  |
| Less:  Distributions to noncontrolling interests                      | (212,792 | ) |   | (214,323 | ) |   | (193,769 | ) |
| Cash provided by operating activities attributable to DaVita Inc.     | 1,833,929 |  |   | 1,814,926 |  |   | 1,724,166 |  |
| Less: Expenditures for routine maintenance and information technology | (347,563 | ) |   | (347,594 | ) |   | (385,067 | ) |
| Free cash flow                                                        | $ | 1,486,366 |  |   | $ | 1,467,332 |  |   | $ | 1,339,099 |  |

----

|                                       |
|---------------------------------------|
|                                       |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                  | Three months ended |   | Nine months ended September 30, 2017 |
|                                  | September 30,2017 |   | June 30,2017 |   | September 30,2016 |   |
| Medical revenues                      | $ | 1,163,272 |  |   | $ | 1,176,992 |  |   | $ | 1,012,907 |  |   | $ | 3,408,967 |  |
| Less: Risk share revenue, net         | (16,018 | ) |   | (36,117 | ) |   | (26,125 | ) |   | (60,786 | ) |
| Add: Institutional capitation amounts | 208,057 |  |   | 213,887 |  |   | 324,699 |  |   | 715,779 |  |
| Total care dollars under management   | $ | 1,355,311 |  |   | $ | 1,354,762 |  |   | $ | 1,311,481 |  |   | $ | 4,063,960 |  |

----

|                                               |
|-----------------------------------------------|
|                                               |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                          | Three months ended September 30, 2017 |   | Nine months ended September 30, 2017 |
|                                          | Consolidated |   |  Kidney Care |   |  DMG |   | Consolidated |   |  Kidney Care |   |  DMG |
| Net (loss) income attributable to DaVita Inc. | $ | (214,476 | ) |   |   |   |   |   | $ | 360,222 |  |   |   |   |   |
| Noncontrolling interests                      | 42,442 |  |   |   |   |   |   | 129,654 |  |   |   |   |   |
| Income tax (benefit) expense                  | (125,742 | ) |   |   |   |   |   | 276,005 |  |   |   |   |   |
| Other income                                  | (4,370 | ) |   |   |   |   |   | (13,866 | ) |   |   |   |   |
| Debt expense                                  | 109,623 |  |   |   |   |   |   | 322,014 |  |   |   |   |   |
| Operating (loss) income                       | (192,523 | ) |   | 395,294 |  |   | (587,817 | ) |   | 1,074,029 |  |   | 1,662,418 |  |   | (588,389 | ) |
| Depreciation and amortization                 | 203,283 |  |   | 142,634 |  |   | 60,649 |  |   | 593,527 |  |   | 415,544 |  |   | 177,983 |  |
| EBITDA                                        | $ | 10,760 |  |   | $ | 537,928 |  |   | $ | (527,168 | ) |   | $ | 1,667,556 |  |   | $ | 2,077,962 |  |   | $ | (410,406 | ) |

----

|                                                               |
|---------------------------------------------------------------|
|                                                               |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                                          | Three months ended September 30, 2017 |   | Nine months ended September 30, 2017 |
|                                                          | Consolidated |   |  Kidney Care |   |  DMG |   | Consolidated |   |  Kidney Care |   |  DMG |
| Net (loss) income attributable to DaVita Inc.                 | $ | (214,476 | ) |   |   |   |   |   | $ | 360,222 |  |   |   |   |   |
| Noncontrolling interests                                      | 42,442 |  |   |   |   |   |   | 129,654 |  |   |   |   |   |
| Income tax (benefit) expense                                  | (125,742 | ) |   |   |   |   |   | 276,005 |  |   |   |   |   |
| Other income                                                  | (4,370 | ) |   |   |   |   |   | (13,866 | ) |   |   |   |   |
| Debt expense                                                  | 109,623 |  |   |   |   |   |   | 322,014 |  |   |   |   |   |
| Operating (loss) income                                       | (192,523 | ) |   | 395,294 |  |   | (587,817 | ) |   | 1,074,029 |  |   | 1,662,418 |  |   | (588,389 | ) |
| Goodwill impairment charges                                   | 601,040 |  |   |   |   | 601,040 |  |   | 686,355 |  |   | 34,696 |  |   | 651,659 |  |
| Equity investment loss related to APAC JV goodwill impairment | 6,293 |  |   | 6,293 |  |   |   |   | 6,293 |  |   | 6,293 |  |   |   |
| Impairment of assets                                          |   |   |   |   |   |   | 15,168 |  |   | 15,168 |  |   |   |
| Restructuring charges                                         | 11,269 |  |   | 1,700 |  |   | 9,569 |  |   | 11,269 |  |   | 1,700 |  |   | 9,569 |  |
| Equity investment loss related to restructuring charges       | 1,000 |  |   | 1,000 |  |   |   |   | 1,000 |  |   | 1,000 |  |   |   |
| Gain on settlement, net                                       |   |   |   |   |   |   | (526,827 | ) |   | (526,827 | ) |   |   |
| Equity investment income related to gain on settlement        |   |   |   |   |   |   | (2,677 | ) |   | (2,677 | ) |   |   |
| Gain on Magan acquisition                                     | (17,129 | ) |   |   |   | (17,129 | ) |   | (17,129 | ) |   |   |   | (17,129 | ) |
| Gain on APAC JV ownership changes                             |   |   |   |   |   |   | (6,273 | ) |   | (6,273 | ) |   |   |
| Accruals for legal matters                                    | (11,100 | ) |   |   |   | (11,100 | ) |   | (14,700 | ) |   |   |   | (14,700 | ) |
| Adjusted operating income (loss)                              | 398,850 |  |   | 404,287 |  |   | (5,438 | ) |   | 1,226,508 |  |   | 1,185,499 |  |   | 41,009 |  |
| Depreciation and amortization                                 | 203,283 |  |   | 142,634 |  |   | 60,649 |  |   | 593,527 |  |   | 415,544 |  |   | 177,983 |  |
| Adjusted EBITDA                                               | $ | 602,133 |  |   | $ | 546,921 |  |   | $ | 55,211 |  |   | $ | 1,820,035 |  |   | $ | 1,601,043 |  |   | $ | 218,992 |  |